Présentation de l'entreprise
Vaxcyte, Inc. operates as a clinical-stage vaccine innovation company dedicated to the development of conjugate and novel protein vaccines designed to prevent or treat bacterial infectious diseases. The enterprise functions within the healthcare sector, specifically the biotechnology industry, where it focuses on high-risk, high-reward research and development cycles typical of early-stage life sciences firms. As of the latest reported data, the company holds a market capitalization of $7.72B and employs a workforce of 507 individuals across its operational footprint. The reported market cap of $7.72B suggests a significant valuation premium relative to its current financial performance, indicating that the market places a high value on the potential of its lead vaccine candidate, VAX-24, despite the absence of reported annual revenue figures in the current dataset. This disparity between market valuation and zero reported revenue highlights the speculative nature of the asset, where investor confidence is driven primarily by intellectual property potential and future commercialization prospects rather than current earnings generation.
Santé financière
The company reports no revenue over the trailing twelve months, resulting in a net income loss of $-766,627,968 and an EBITDA of $-907,278,976, which underscores a cost structure heavily weighted toward research and development expenditures rather than commercial sales. The free cash flow stands at $-430,852,864, reflecting a substantial cash burn rate that necessitates continuous capital raising or the utilization of existing cash reserves to fund ongoing clinical trials and operational expenses. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that accurately represents a pre-revenue stage where traditional profitability measures are not applicable due to the lack of sales data. On the balance sheet, the company holds $1.56B in cash against total debt of $117.48M, creating a robust liquidity buffer that supports its long-term R&D initiatives. The debt-to-equity ratio is calculated at 4.38, indicating a leveraged capital structure where equity financing is significantly lower than debt obligations, yet the massive cash hoard mitigates immediate solvency risks. Short-term liquidity is exceptionally strong, evidenced by a current ratio of 7.91, which signifies that the company possesses nearly eight times the current assets necessary to cover its current liabilities. Return on Equity is reported at -25.6% and return on assets at -17.7%, metrics that reveal management's current inability to generate positive returns from shareholder capital or total assets, a common characteristic for clinical-stage biotechnology entities prior to product launch.
Évaluation de la valorisation
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is reported at -7.29, a negative multiple that implies the market is pricing in future earnings recovery or continued losses in the near term. The price-to-book ratio stands at 2.59, suggesting that the market values the company at a 159% premium over its book value, reflecting the intangible worth of its pipeline assets and regulatory potential. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -6.84, which further illustrates that traditional valuation multiples are distorted by the absence of profitability and sales data. The stock has traded between a 52-week low of $27.66 and a 52-week high of $75.33, with the current price positioning relative to this range dependent on real-time market fluctuations not detailed in the static dataset. The beta value is 1.38, indicating that the stock exhibits higher volatility than the broader market, moving approximately 38% more aggressively in response to market-wide shifts. This elevated beta suggests that price movements for Vaxcyte, Inc. are likely to be amplified during periods of market stress or sector-specific optimism, requiring investors to tolerate greater price swings.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated significant commercial sales to calculate meaningful growth rates. The absence of these growth metrics implies that the company is not yet in a phase where earnings are expanding faster than revenue, as both are currently non-existent or negligible. Vaxcyte, Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available cash flow back into research, development, and clinical operations rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential for future product commercialization and the depletion of its $1.56B cash reserve rather than current cash distributions or revenue expansion.